MARKET

CLSN

CLSN

Celsion
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.8700
-0.0300
-3.33%
After Hours: 0.8601 -0.0099 -1.14% 19:59 01/15 EST
OPEN
0.9000
PREV CLOSE
0.9000
HIGH
0.9199
LOW
0.8540
VOLUME
3.06M
TURNOVER
--
52 WEEK HIGH
6.50
52 WEEK LOW
0.4305
MARKET CAP
32.55M
P/E (TTM)
-1.1888
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Implied Volatility Surging for Celsion (CLSN) Stock Options
Investors need to pay close attention to Celsion (CLSN) stock based on the movements in the options market lately.
Zacks · 12/11/2020 13:53
Do Hedge Funds Love Celsion Corporation (CLSN)?
The Insider Monkey team has completed processing the quarterly 13F filings for the September quarter submitted by the hedge funds and other money managers included in our extensive database. Most hedge fund investors experienced strong gains on the back of a strong market performance, which certainly propelled them to adjust their equity holdings so as […]
Insider Monkey · 11/26/2020 23:31
New Strong Sell Stocks for November 19th
Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today.
Zacks · 11/19/2020 15:02
Celsion slips 4% on Q3 earnings miss
Celsion ([[CLSN]] -4.1%) Q3 resultsRevenue of $0.13M (unch).Net loss: ($8.1M) (-47.3%); loss/share: ($0.24) (+7.7%).CF Ops: ($11.9M) vs ($16.2M) a year ago.Cash and cash equivalents of $18.3M. In July 2020, initiates Phase II OVATION
Seekingalpha · 11/16/2020 15:55
Celsion Corp. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / November 16, 2020 / Celsion Corp.
ACCESSWIRE · 11/16/2020 14:15
Celsion: Q3 Earnings Insights
Shares of Celsion (NASDAQ:CLSN) remained unaffected after the company reported Q3 results.Quarterly Results Earnings per share increased 32.00% over the past year to ($0.17), which missed the estimate of ($0.13).Revenue of $125,000 unchanged by 0.00% year over year, which beat the estimate of $80,000.Outlook Earnings guidance hasn't been issued by the company for now.Celsion hasn't issued any revenue guidance for the time being.Details Of The Call Date: Nov 16, 2020View more earnings on CLSNTime: 11:00 AMET Webcast URL: https://edge.media-server.com/mmc/p/n6e4r5nwPrice Action Company's 52-week high was at $6.5052-week low: $0.43Price action over last quarter: down 51.53%Company Overview Celsion Corp is active in the biotechnology market. The company acts as a drug developer with product candidates like ThermoDox, a heat-activated liposomal encapsulation of doxorubicin. It is in Phase III clinical trial for the treatment of primary liver cancer and a Phase II clinical trial for the treatment of recurrent chest wall breast cancer. Its pipeline also includes GEN-1, a deoxyribonucleic acid (DNA) mediated immunotherapy for the localized treatment of ovarian and brain cancers.See more from Benzinga * Click here for options trades from Benzinga * Earnings Scheduled For November 16, 2020 * Stocks That Hit 52-Week Lows On Monday(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga · 11/16/2020 13:44
Celsion Q3 Adj. EPS $(0.17) Misses $(0.13) Estimate, Sales $125.00K Beat $80.00K Estimate
Celsion (NASDAQ:CLSN) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of $(0.13) by 30.77 percent. This is a 32 percent increase over losses of $(0.25) per share from the same
Benzinga · 11/16/2020 13:33
The Week Ahead In Biotech: The Vaccine Updates, Drug Presentations, And FDA Decisions That Will Move The Markets
Biotech stocks advanced in the week ended Nov. 13 amid a vaccine news flow-induced rally that also lifted the broader market.
Benzinga · 11/15/2020 15:14
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CLSN. Analyze the recent business situations of Celsion through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CLSN stock price target is 4.000 with a high estimate of 5.00 and a low estimate of 3.000.
EPS
Institutional Holdings
Institutions: 60
Institutional Holdings: 5.17M
% Owned: 13.82%
Shares Outstanding: 37.42M
TypeInstitutionsShares
Increased
12
1.58M
New
17
254.07K
Decreased
8
797.28K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.34%
Pharmaceuticals & Medical Research
+0.21%
Key Executives
Chief Financial Officer/Senior Vice President/Secretary/IR Contact Officer
Jeffrey Church
Executive Vice President
Khursheed Anwer
Senior Vice President
Nicholas Borys
Director/Chief Executive Officer/President/Chairman
Michael Tardugno
Independent Director
Donald Braun
Independent Director
Pok Yu Chow
Independent Director
Frederick Fritz
Independent Director
Robert Hooper
Independent Director
Andreas Voss
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About CLSN
Celsion Corporation is an oncology drug development company. The Company's product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study). Its pipeline also includes GEN-1, a deoxyribonucleic acid (DNA) mediated immunotherapy for the localized treatment of ovarian and brain cancers. It has over three platform technologies for the development of treatments for those suffering with difficult-to-treat forms of cancer, including Lysolipid Thermally Sensitive Liposomes, a heat sensitive liposomal based dosage form that targets disease with known therapeutics in the presence of mild heat; TheraPlas, a nucleic acid-based treatment for local transfection of therapeutic plasmids, and TheraSilence, a systemic dosage form for lung directed anti-cancer ribonucleic acid (RNA).
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Celsion Corporation stock information, including NASDAQ:CLSN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLSN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CLSN stock methods without spending real money on the virtual paper trading platform.